Literatur
Vincenti F, Rostaing L, Grinyo J, Rice K, Steinberg S, Gaite L, Moal MC, Mondragon-Ramirez GA, Kothari J, Polinsky MS et al (2016) Belatacept and long-term outcomes in kidney transplantation. N Engl J Med 374:333–343. doi:10.1038/ejcn.2015.174
Rostaing L, Vincenti F, Grinyo J, Rice KM, Bresnahan B, Steinberg S, Gang S, Gaite LE, Moal MC, Mondragon-Ramirez GA et al (2013) Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study. Am J Transplant 13:2875–2883
Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, Massari P, Mondragon-Ramirez GA, Agarwal M, Di Russo G et al (2010) A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 10:535–546
Vincenti F, Larsen CP, Alberu J, Bresnahan B, Garcia VD, Kothari J, Lang P, Urrea EM, Massari P, Mondragon-Ramirez G et al (2012) Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 12:210–217
Florman SM, Rial M, Medina J (2015) Final results from the BENEFIT-EXT trial: a 7 year follow-up of belatacept treated patients. Am J Transplant 15(Suppl 3):Abstract
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
J. Lutz gibt an, dass kein Interessenkonflikt besteht.
Additional information
Redaktion
T. Feldkamp, Kiel
J. Lutz, Mainz
L. T. Weber, Köln
Rights and permissions
About this article
Cite this article
Lutz, J. Belatacept verbessert Langzeitverlauf nach Nierentransplantation. Nephrologe 11, 355–356 (2016). https://doi.org/10.1007/s11560-016-0079-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11560-016-0079-9